Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078314" target="_blank" >RIV/65269705:_____/23:00078314 - isvavai.cz</a>
Result on the web
<a href="https://haematologica.org/article/view/haematol.2022.281754" target="_blank" >https://haematologica.org/article/view/haematol.2022.281754</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2022.281754" target="_blank" >10.3324/haematol.2022.281754</a>
Alternative languages
Result language
angličtina
Original language name
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
Original language description
Hairy cell leukemia (HCL) is a rare indolent B-cell neoplasm accounting for 2% of leukemias, with an estimated incidence of <1 case per 100,000 population.1 Purine analogs such as cladribine and pentostatin are potent agents in HCL with complete remission (CR) rates approaching 75-90% with monotherapy.2,3 Despite these response rates, there is no evidence of cure and the majority of patients experience recurrence of the disease and require multiple treatments; repeated exposure to purine analogs yields lower response rates and shorter durations of remission.2 Moreover, the distinct, variant subtype of HCL (HCLv) is more resistant to standard purine analogs,4 so the median overall survival from diagnosis of patients with HCLv is 6-9 years compared to >25 years for those with classical HCL.4-6 First-line chemoimmunotherapy, adding rituximab concurrently with or after treatment with a purine analog, improved CR rates with longer remission periods in both HCL and HCLv.5,7,8 However, treatment for 'high-risk' patients and those with disease resistant to purine analogs remains challenging. Allogeneic hematopoietic cell transplant (allo-HCT) can potentially produce long-term remission in many diseases, including chronic leukemias; however, evidence to support the use of allo-HCT in refractory/multiple relapsed HCL has been limited to case reports only.9
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Haematologica
ISSN
0390-6078
e-ISSN
1592-8721
Volume of the periodical
108
Issue of the periodical within the volume
6
Country of publishing house
IT - ITALY
Number of pages
4
Pages from-to
1676-1679
UT code for WoS article
001023596100026
EID of the result in the Scopus database
2-s2.0-85152879786